気管支喘息および慢性関節リウマチにおける気道抵抗(sRaw)および気道コンダクタンス(sGaw)に対するサルブタモールまたはクロモリン吸入の影響

書誌事項

タイトル別名
  • Effects of salbutamol and disodium cromoglycate on Specific Airway Resistance (sRaw) and Specific Conductance (sGaw) in Bronchial asthma and Rheunmatoid arthritis.

この論文をさがす

抄録

サルブタモールまたはdisodium cromoglycate(クロモリン)吸入液を,気管支喘息(以下BA)6例,慢性関節リウマチ(以下RA)7例,正常対照5例に吸入させ,吸入前および吸入後約30分に,気道抵抗(sRaw)と気道コンダクタンス(sGaw)を,定容積型体プレチスモグラフ(Sensor Medics Corporation, Anaheim, California, made in U.S.A.)を用いて測定した。吸入前の値をsGawで比較すると,BAはRAや正常対照に比べ有意に閉塞の程度が強く,RAと正常対照の間では有意な差はなかった。サルブタモール吸入の場合,BAでは吸入後にsRawおよびsGawの有意な改善(P<0.01)がみられ,それらの改善率(%)は,RAや正常対照と比べて有意に高く(P<0.01),RAと正常対照の間では改善率の有意な差は認めなかった。クロモリン吸入の場合,いずれの群においても,sRawおよびsGawの吸入後の変化に有意差はみられなかったが,BAにおいて,sRawの改善率(%)はRAと正常対照に対して,またsGawの改善率(%)は正常対照に対して有意に高く(P<0.05),RAと正常対照の間では,sRaw,sGaw共に改善率(%)の明らかな差はみられなかった。

We examined effects of salbutamol sulfate and disodium cromoglycate (cromolyn) on specific airway resistance (sRaw) and specific conductance (sGaw) in 6 patients with bronchial asthma (BA), 7 patients with rheumatoid arthritis (RA), and 5 subjects of controls, using a constant volume, whole body plethysmograph (Sensor Medics Corporation, Anaheim, California, U.S.A.). The results before and 30 minutes after inhalation of agents were compared to evaluate their effects on sRaw and sGaw. Before inhalation, the sGaw of BA was significantly lower than that of RA or controls, and there was no difference between that of RA and normal controls. The sGaw and sRaw in BA were significantly improved (P<0.01) after inhalation of salbutamol and those improvement after inhalation were significantly higher (P<0.01) in BA than those in RA or controls, however there was no difference between those of RA and controls. Although there was no sigificant change of sGaw and sRaw in all groups between before and after inhalation of cromolyn, the improvement of sRaw after inhalation was significantly higher in BA than in RA or controls (P<0.05), and that of sGaw was significantly higher in BA than in controls (P<0.05).

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ